Ambrosia Biosciences
Develops orally delivered, small molecule-based therapies for obesity and other metabolic disorders
$100MSeries B
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops orally delivered, small molecule-based therapies for obesity and other metabolic disorders
Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions
Pitching Janus Henderson Investors? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room